NCT07427576Completed
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid®/Clustek®/Alxoid® for the Treatment of Dermatophagoides/Blomia Tropicalis Allergy in Real-Life Conditions
Source: ClinicalTrials.gov · Last updated 23 Feb 2026
Brief summary (registry, in English)
House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with rhinoconjunctivitis due to sensitisation to these mites (94.7%). Immunotherapy is indicated for the treatment of allergic rhinoconjunctivitis and is capable of altering the natural course of allergic diseases. The aim of the study was to evaluate the efficacy and safety of Clustoid® Max Forte in the treatment of patients with respiratory allergy to Dermatophagoides/Blomia tropicalis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 140 (actual)
- First submitted
- 30 Jan 2026
- Start date
- 31 Mar 2025
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Inmunotek S.L.
- Diseases
- Asthma
- NCT number
- NCT07427576
What you commit to
- Study type: Observational
- Participants enrolled: 140
- From 31 Mar 2025 to the primary completion date, 31 Aug 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1.Patients who have received immunotherapy with airborne allergens prior to the treatment to be evaluated in this study.
Who the study is looking for
- The study population consists of patients with respiratory allergic disease who are indicated for treatment with Clustoid® Max Forte immunotherapy according to standard clinical practice.
- Age between 5 and 65 years, with no gender differences.
- Who have received immunotherapy for at least one year.
Age in the registry: 5 years to 65 years · Sex: All
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuestra Señora de Candelaria Coordinator of this site? Confirm its status | Santa Cruz de Tenerife | Spain | Unknown status |
| Clínica Doctor García Robaina Coordinator of this site? Confirm its status | Santa Cruz de Tenerife | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.